$1.22 Billion is the total value of PFM Health Sciences, LP's 61 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MCK | New | MCKESSON CORP | $46,523,000 | – | 343,950 | +100.0% | 3.82% | – |
| New | BIOMARIN PHARMACEUTICAL INCnote 0.599% 8/0 | $43,421,000 | – | 41,600,000 | +100.0% | 3.57% | – | |
| CAH | New | CARDINAL HEALTH INC | $42,117,000 | – | 878,531 | +100.0% | 3.46% | – |
| BDX | New | BECTON DICKINSON & CO | $34,730,000 | – | 151,150 | +100.0% | 2.85% | – |
| ABC | New | AMERISOURCEBERGEN CORP | $29,978,000 | – | 338,732 | +100.0% | 2.46% | – |
| HRTX | New | HERON THERAPEUTICS INC | $29,138,000 | – | 2,481,917 | +100.0% | 2.39% | – |
| BAX | New | BAXTER INTL INC | $25,139,000 | – | 309,635 | +100.0% | 2.06% | – |
| JNJ | New | JOHNSON & JOHNSON | $21,817,000 | – | 166,375 | +100.0% | 1.79% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $14,126,000 | – | 97,864 | +100.0% | 1.16% | – |
| SAGE | New | SAGE THERAPEUTICS INC | $12,536,000 | – | 436,477 | +100.0% | 1.03% | – |
| RCUS | New | ARCUS BIOSCIENCES INC | $11,236,000 | – | 809,511 | +100.0% | 0.92% | – |
| AMZN | New | AMAZON COM INC | $10,415,000 | – | 5,342 | +100.0% | 0.86% | – |
| CNST | New | CONSTELLATION PHARMCETICLS I | $9,929,000 | – | 315,894 | +100.0% | 0.82% | – |
| XLNX | New | XILINX INC | $9,717,000 | – | 124,677 | +100.0% | 0.80% | – |
| IGMS | New | IGM BIOSCIENCES INC | $9,158,000 | – | 163,105 | +100.0% | 0.75% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $8,904,000 | – | 81,804 | +100.0% | 0.73% | – |
| PPD | New | PPD INC | $8,509,000 | – | 477,743 | +100.0% | 0.70% | – |
| DCPH | New | DECIPHERA PHARMACEUTICALS IN | $8,495,000 | – | 206,336 | +100.0% | 0.70% | – |
| IMMU | New | IMMUNOMEDICS INCcall | $6,035,000 | – | 447,700 | +100.0% | 0.50% | – |
| DE | New | DEERE & CO | $5,555,000 | – | 40,208 | +100.0% | 0.46% | – |
| XLRN | New | ACCELERON PHARMA INC | $5,518,000 | – | 61,400 | +100.0% | 0.45% | – |
| ZLAB | New | ZAI LAB LTDadr | $4,344,000 | – | 84,387 | +100.0% | 0.36% | – |
| SHOP | New | SHOPIFY INCcl a | $3,942,000 | – | 9,454 | +100.0% | 0.32% | – |
| INSM | New | INSMED INC | $3,667,000 | – | 228,781 | +100.0% | 0.30% | – |
| NEE | New | NEXTERA ENERGY INC | $3,205,000 | – | 13,320 | +100.0% | 0.26% | – |
| New | ACORDA THERAPEUTICS INCnote 1.750% 6/1 | $1,721,000 | – | 2,000,000 | +100.0% | 0.14% | – | |
| MYOK | New | MYOKARDIA INC | $1,669,000 | – | 35,592 | +100.0% | 0.14% | – |
| ALNA | New | ALLENA PHARMACEUTICALS INC | $274,000 | – | 284,285 | +100.0% | 0.02% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MOLINA HEALTHCARE INC | 41 | Q3 2023 | 2.2% |
| HCA HOLDINGS INC | 38 | Q3 2023 | 5.2% |
| HUMANA INC | 37 | Q3 2023 | 3.8% |
| EDWARDS LIFESCIENCES CORP | 36 | Q3 2023 | 3.3% |
| UNITEDHEALTH GROUP INC | 33 | Q3 2023 | 4.8% |
| PENUMBRA INC | 33 | Q3 2023 | 4.8% |
| AERIE PHARMACEUTICALS INC | 28 | Q2 2022 | 3.7% |
| TENET HEALTHCARE CORP | 27 | Q3 2023 | 2.3% |
| ELEVANCE HEALTH INC | 26 | Q3 2023 | 4.2% |
| ICON PLC | 26 | Q3 2023 | 2.5% |
View PFM Health Sciences, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adaptimmune Therapeutics PLC | February 14, 2023 | ? | ? |
| Arcus Biosciences, Inc. | February 14, 2023 | ? | ? |
| Axsome Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Erasca, Inc. | February 14, 2023 | ? | ? |
| Generation Bio Co. | February 14, 2023 | ? | ? |
| IO Biotech, Inc. | February 14, 2023 | ? | ? |
| Jounce Therapeutics, Inc. | February 14, 2023 | ? | ? |
| Outset Medical, Inc. | February 14, 2023 | ? | ? |
| uniQure N.V. | February 14, 2023 | ? | ? |
| AERIE PHARMACEUTICALS INC | February 14, 2022 | ? | ? |
View PFM Health Sciences, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G | 2023-04-21 |
View PFM Health Sciences, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.